Active Ingredient History
Volasertib is an experimental small molecule inhibitor of the PLK1 protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Non-Small-Cell Lung (Phase 2)
Leukemia (Phase 1)
Leukemia, Erythroblastic, Acute (Phase 1)
Leukemia, Megakaryoblastic, Acute (Phase 1)
Leukemia, Monocytic, Acute (Phase 1)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myelomonocytic, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Lymphoma (Phase 1)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue